Aβ Variants and Their Impact on Amyloid Formation and Alzheimer’s Disease Progression
Publisher
Springer London
Reference119 articles.
1. Klucken, J., McLean, P.J., Gomez-Tortosa, E., et al. Neuritic alterations and neural system dysfunction in Alzheimer’s disease and dementia with Lewy bodies. Neurochem. Res. 2003; 28:1683–1691.
2. Ghiso, J., and Frangione, B. Amyloidosis and Alzheimer’s disease. Adv. Drug Deliv. Rev. 2002; 54:1539–1551.
3. Giasson, B.I., Lee, V.M.Y., and Trojanowski, J.Q. Interactions of amyloidogenic proteins. Neuromol. Med. 2003; 4:49–58.
4. Knauer, M.F., Soreghan, B., Burdick, D., et al. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/β protein. Proc. Natl. Acad. Sci. U. S. A. 1992; 89:7437–7441.
5. Tabaton, M., Nunzi, M.G., Xue, R., et al. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem. Biophys. Res. Commun. 1994; 200:1598–1603.